Market Size – USD 1297.3 Million in 2019, Market Growth – CAGR of 6.2%, Market Trends– Rising prevalence of target disease and favorable reimbursement scenario is expected to fuel the market in the forecast period.
According to the current analysis of Emergen Research, the global Diabetic Ketoacidosis Market was valued at USD 1297.3 million in 2019 and is expected to reach USD 1973.6 million by 2027, at a CAGR of 6.2%. Increasing awareness among healthcare professionals about ketones build up during type 1 diabetes as well as type 2 diabetes, and favorable funding scenario for drug development and technological advancements in diabetes ketoacidosis treatment is anticipated to boost the growth of the market during the forecast period. Ketoacidosis, hyperglycemia and ket onuria during diabetic ketoacidosis makes it a critical life threatening condition of diabetes.
Furthermore, growing prevalence of type 1 diabetes across the globe, increasing availability of well-organized and technologically advanced diabetic ketoacidosis treatment in developing nations, significant R&D activities by the existing and emerging market players to develop effective drugs in an attempt to cater the demand supply gap in the market.
Key players in the market include Biocon, Merck, Novo Nordisk, Bristol-Myers Squibb, AstraZeneca, Sanofi, Pfizer, Eli Lilly and Company, Tonghua Dongbao Pharmaceutical, Wockhardt, GlaxoSmithKline, Oramed Pharmaceuticals and Adocia among other companies
Browse complete report description and visit our website @ https://www.emergenresearch.com/industry-report/diabetic-ketoacidosis-market
Regional Scope: North America; Europe; Asia Pacific; Central & South America; MEA
Treatment Type Outlook (Revenue in Million USD; 2017–2027)
- Fluid Replacement
- Electrolyte Replacement
- Insulin Therapy
- Intermediate-Acting Insulin
- Long-Acting Insulin
End Use Outlook (Revenue in Million USD; 2017–2027)
- Hospitals
- Ambulatory Care Centre
- Specialty Clinics
North America accounted for the largest market share of approximately, 37.2% in the global Diabetic Ketoacidosis market in 2019 primarily due to growing incidences of chronic asthma and rhinosinusitis symptoms along with competent infrastructure and favorable reimbursement scenarios. Owing to such promising market drivers, the North American market is anticipated to grow significantly through the forecast period.
Thank you for reading our report. For further information or queries about the report or customization options, please get in touch with us. We will ensure your report is tailored according to your requirements.
